Effect of Nintedanib in Patients with Limited and Extensive Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS Trial - Goh, N; Denton, C P; Lynch, D A (A37 ILD Ther I, 2020)
et al.